Malignant Melanoma is the most aggressive form of skin cancer. Worldwide, the incidence of melanoma has risen sharply of the past three decades. On the 1st of January 2007, there were nearly 800,000 people alive in the USA alone, who were diagnosed with a melanoma. This increase is characterized largely by an increase in thin melanomas (1 mm or less; T1 tumors). Prognosis of American Joint Committee on Cancer (AJCC) stage I / II ranges between 95% for T1 and 45% for T4 melanomas.

Additional Metadata
Keywords malignant melanoma, skin cancer
Promotor A.M.M. Eggermont (Alexander)
Publisher Erasmus University Rotterdam
Sponsor Afdeling Heelkunde Erasmus MC, Boehringer-Ingelheim, Erasmus MC, Esaote – Pie Medical Benelux, Jurriaanse Stichting, Eucerin, Novartis, Provectus, Stichting Erasmus Heelkundig Kanker Onderzoek (SEHK), Provectus Pharmaceuticals
ISBN 978-90-8559-320-1
Persistent URL
van Akkooi, A.C.J. (2011, January 19). Sentinel Node Tumor Load Assessment in Melanoma: Dilemmas and Clinical Management. Erasmus University Rotterdam. Retrieved from